

**Supplementary Material****Baricitinib further enhances disease modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.**

Pedro López-Romero, Inmaculada de la Torre, Ewa Haladyj, Daniel Aletaha, Josef S Smolen

Supplemental Table 1A and B. CDAI change from baseline in patients with averaged CDAI >10 in RA-BEAM (MTX-IR patients with established RA) and RA-BEGIN (csDMARD naïve patients with early RA).

<b>RA-BEAM</b>				
		PBO	Bari 4 mg	ADA
Average CDAI>10 up to week 24				
N (%)		257 (39.1%)	236 (35.9%)	164 (25.0%)
Change from baseline in CDAI <sup>a</sup>		-17.26	-22.78	-22.30
Difference vs. PBO		-	-5.52	-5.03
P-value vs. PBO		-	<0.001	<0.001
<b>Change from baseline in mTSS<sup>b</sup></b>				
Change from baseline in mTSS <sup>b</sup>	CDAI >10	0.84	0.34	0.28
	CDAI ≤10	0.31	0.24	0.15
Within group p-value		0.02	0.6	0.5

<sup>a</sup>Observed values. <sup>b</sup>Adjusted values. ADA=adalimumab; bari=baricitinib; CDAI=clinical disease activity index; IR=inadequate response; mTSS=modified Total Sharp Score; PBO=PBO; RA=rheumatoid arthritis.

<b>RA-BEGIN</b>				
		MTX	Bari 4 mg	Bari 4 mg + MTX
Average CDAI>10 up to week 52				
N (%)		81 (41.3%)	53 (27.0%)	62 (31.6%)
Change from baseline in CDAI <sup>a</sup>		-24.77	-26.41	-27.04
Difference vs. MTX		-	-1.65	-2.27
P-value vs. MTX		-	0.196	0.062
<b>Change from baseline in mTSS<sup>b</sup></b>				
Change from baseline in mTSS <sup>b</sup>	CDAI >10	1.69	1.05	0.50
	CDAI ≤10	0.43	0.39	0.28
Within group p-value		<0.001	0.07	0.5

<sup>a</sup>Observed values. <sup>b</sup>Adjusted values. bari=baricitinib; CDAI=clinical disease activity index; csDMARD=conventional synthetic disease modifying antirheumatic drugs; mTSS=modified Total Sharp Score; MTX=methotrexate; RA=rheumatoid arthritis.

Supplemental Table 2A and B. hsCRP change from baseline in patients with averaged hsCRP >5 mg/L in RA-BEAM (MTX-IR patients with established RA) and RA-BEGIN (csDMARD naïve patients with early RA).

RA-BEAM				
		PBO	Bari 4 mg	ADA
Average hsCRP >5 mg/L up to week 24				
N (%)		257 (50.1%)	149 (29.0%)	107 (20.9%)
Change from baseline in hsCRP <sup>a</sup>		-2.23	-8.84	-2.98
Difference vs. PBO		-	-6.61	-0.75
P-value vs. PBO		-	<0.001	0.636
Change from baseline in mTSS <sup>b</sup>	hsCRP >5 mg/L	0.85	0.40	0.30
	hsCRP ≤5 mg/L	0.37	0.21	0.17
Within group p-value		0.03	0.3	0.5

<sup>a</sup>Observed values. <sup>b</sup>Adjusted values. ADA=adalimumab; bari=baricitinib; hsCRP=high sensitivity C-reactive protein; IR, inadequate response; mTSS=modified Total Sharp Score; PBO=PBO; RA=rheumatoid arthritis.

RA-BEGIN				
		MTX	Bari 4 mg	Bari 4 mg + MTX
Average hsCRP >5 mg/L up to week 52				
N (%)		81 (44.5%)	54 (29.7%)	47 (25.8%)
Change from baseline in hsCRP <sup>a</sup>		-9.44	-11.15	-13.37
Difference vs. MTX		-	-1.71	-3.94
P-value vs. MTX		-	0.354	0.045
Change from baseline in mTSS <sup>b</sup>	hsCRP >5 mg/L	1.51	1.20	-0.15
	hsCRP ≤5 mg/L	0.77	0.31	0.52
Within group p-value		0.03	0.01	0.06

<sup>a</sup>Observed values. <sup>b</sup>Adjusted values. bari=baricitinib; csDMARD=conventional synthetic disease modifying antirheumatic drugs; hsCRP, high sensitivity C-reactive protein; mTSS=modified Total Sharp Score; MTX=methotrexate; RA=rheumatoid arthritis.